Building the precision category in neovascular retinal diseases
Revolutionizing severe retinal disease care with first-in-class non-invasive topical therapies
A united team dedicated to bringing novel therapies in focus for patients
Bringing new visions to life for patients
Our mission is to revolutionize eye care with innovative, non-invasive treatments, giving patients a brighter, clearer vision to life.
About Us
Roca Therapeutics’ team is comprised of international industry and top notch research experts in VEGF-independent mechanisms of angiogenesis and inflammation, and in the development of new therapies based on first-in-class small molecules.
Learn more about RCT002 for neovascular retinal diseases
RCT002 has been granted orphan drug designation by the EMA and is being developed as a topical administration to treat radiation maculopathy with a quick follow indication in diabetic macular edema. RCT002 modifies disease by blocking resistant angiogenesis, oxidative stress, inflammation, and fibrosis.